Despite the major advances in the management of HIV infection, HIV-infected patients still have greater morbidity and mortality than the general population. Serious non-AIDS events (SNAEs), including non-AIDS malignancies, cardiovascular events, renal and hepatic disease, bone disorders and neurocognitive impairment, have become the major causes of morbidity and mortality in the antiretroviral therapy (ART) era. SNAEs occur at the rate of 1 to 2 per 100 person-years of follow-up. The pathogenesis of SNAEs is multifactorial and includes the direct effect of HIV and associated immunodeficiency, underlying co-infections and co-morbidities, immune activation with associated inflammation and coagulopathy as well as ART toxicities. A number of novel strategies such as ART intensification, treatment of co-infection, the use of anti-inflammatory drugs and agents that reduce microbial translocation are currently being examined for their potential effects in reducing immune activation and SNAEs. However, currently, initiation of ART before advanced immunodeficiency, smoking cessation, optimisation of cardiovascular risk factors and treatment of HCV infection are most strongly linked with reduced risk of SNAEs or mortality. Clinicians should therefore focus their attention on addressing these issues prior to the availability of further data.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3874658 | PMC |
| http://dx.doi.org/10.1186/1742-6405-10-29 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparison of clinical outcomes of pulmonary nocardiosis between AIDS and non-AIDS patients.
BMC Infect Dis
June 2024
Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, 10700, Thailand.
Article Synopsis
- Nocardia species can infect both healthy and immunocompromised individuals, prompting a study comparing outcomes in AIDS and non-AIDS patients with pulmonary nocardiosis in northeastern Thailand from 2009 to 2022.
- The study found that AIDS patients had higher rates of severe complications and mortality, particularly those with disseminated disease, highlighting a 7.93-fold increased risk of death within 30 days compared to non-AIDS patients.
- The authors conclude that early diagnosis and a multidrug treatment approach are crucial for managing pulmonary nocardiosis in resource-limited settings, especially for AIDS patients.
Low Level Viremia Is Associated With Serious non-AIDS Events in People With HIV.
Open Forum Infect Dis
April 2024
Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
Background: The consequences of low-level viremia in people with HIV are unclear. We used data from the US Military HIV Natural History Study to examine the association of low-level viremia (LLV) and serious non-AIDS events (SNAEs).
Methods: Included participants initiated antiretroviral therapy after 1996 and had ≥3 viral loads (VLs) measured, using an assay with a lower limit of detection of <50 copies/mL, ≥6 months after antiretroviral therapy initiation.
Comparison of Integrase Strand Transfer Inhibitors (INSTIs) and Protease-Boosted Inhibitors (PIs) on the Reduction in Chronic Immune Activation in a Virally Suppressed, Mainly Male Population Living with HIV (PLWH).
Medicina (Kaunas)
February 2024
1st Department of Internal Medicine, Laiko General Hospital, National and Kapodistrian University of Athens Medical School, 11527 Athens, Greece.
Article Synopsis
- The study investigates the immunological and metabolic health of people living with HIV (PLWH) on combined antiretroviral therapy (cART) at Laiko General Hospital in Athens, focusing on potential health issues compared to the general population.
- It examines specific plasma markers and compares those receiving integrase strand transfer inhibitors (INSTIs) and protease inhibitors (PIs), finding higher IL-6 levels in the PIs group and normal-range LBP mostly in the INSTIs group.
- Overall, glucose, total cholesterol, and LDL cholesterol levels increased after viral suppression, particularly in the PIs group, although many other parameters showed no significant differences between the treatment groups.
Long-term efficacy and safety of a treatment strategy for HIV infection using protease inhibitor monotherapy: 8-year routine clinical care follow-up from a randomised, controlled, open-label pragmatic trial (PIVOT).
EClinicalMedicine
March 2024
MRC Clinical Trials Unit at University College London, London, UK.
Background: Treatment-simplification strategies are important tools for patient-centred management. We evaluated long-term outcomes from a PI monotherapy switch strategy.
Methods: Eligible participants attending 43 UK treatment centres had a viral load (VL) below 50 copies/ml for at least 24 weeks on combination ART.
Characterization and outcomes of difficult-to-treat patients starting modern first-line ART regimens: Data from the ICONA cohort.
Int J Antimicrob Agents
January 2024
Institute for Global Health, UCL, Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), London, United Kingdom.
Article Synopsis
- The study analyzed treatment failures among people with HIV (PWH) undergoing modern antiretroviral therapy (ART), identifying a group defined as 'difficult to treat' (DTT) based on multiple treatment failures over time.
- Out of 8,061 PWH, 320 (or 4%) were categorized as DTT, with a significant higher incidence rate of being DTT (6.5%) after six years, particularly among older individuals with more advanced HIV disease.
- The DTT group faced significantly higher risks of viral failures, treatment failures, and serious health events, indicating they are a more vulnerable population in terms of treatment response.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!